Effective myeloid cell replacement in atherosclerotic plaques after CD45-ADC conditioning. (A) Schematic illustration of the experimental design for atherosclerosis induction and CD45-ADC treatment and ubiquitin-GFP HSCT in Ldlr KO mice. (B) Representative flow plots showing the degree of GFP chimerism in the peripheral blood and bone marrow, 6 weeks after CD45-ADC treatment and HSCT in atherosclerotic Ldlr KO mice. (C) Bar graphs displaying the flow cytometric analysis of GFP chimerism in peripheral blood and bone marrow cell subsets, 6 weeks after CD45-ADC treatment and HSCT in atherosclerotic Ldlr KO mice. (D) FACS plot representative of hematopoietic GFP chimerism in aortic atherosclerotic lesions from Ldlr KO mice, 6 weeks after treatment with CD45-ADC and HSCT. (E) Immunofluorescence images of aortic roots from Ldlr KO mice stained for GFP (green) and DAPI (blue). Dashed lines outline atherosclerotic plaque surface area. Scale bar, 200 μm. (F) GFP chimerism in myeloid cell populations infiltrating aortic atherosclerotic plaques, 6 weeks after CD45-ADC treatment and HSCT of Ldlr KO mice, presented as bar graphs. CMP, common myeloid progenitor; GMP, granulocyte-monocyte progenitor; MEP, megakaryocyte-erythroid progenitor.